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ABSTRACT
I ntroduction: Transcatheter aortic valve replacement (TAVR) is a relatively new strategy
for replacing the aortic valve. We elected to review our early experience to see if we
could identify clinical characteristics at baseline or immediately following the procedure
that would predict death within one year.
Methods: Charts for all patients assigned to receive TAVR procedure at St Mary’s Medical
Center, Huntington, West Virginia between April 2013 and November 2016 were
identified and reviewed. A total of seventy-two cases were included.
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Results : All-cause mortality rate at index hospitalization, 30 days, and 12 months was
5.6%(N=4), 6.9%(N=5), 19.4%(N=14) respectively. Stroke rate at index hospitalization,
30 days, and 12 months was 2.8%(N=2), 2.8%(N=2), 8.3%(N=6) respectively. Major
predictors of death were post procedure GFR, contrast volume, and number of
antiplatelet agents therapy (AUC= 0.638, 0.632, 0.637 respectively).
Conclusion: We found that post procedure GFR, less number of antiplatelet agents post
procedure, and contrast volume may predict mortality within first 12 months post TAVR.
Further studies focused on the above factors may be warranted.
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INTRODUCTION
Transcatheter aortic valve replacement (TAVR) is a
relatively new strategy for replacing the aortic valve
in patients with severe aortic stenosis (AS) who
are felt to be at significant or prohibitive risk for
conventional surgical approach.1 The positive results
from various randomized controlled trials (RCTs) led
to rapid evolution of the procedure.2-4 Both balloonexpandable and self-expandable valves showed
comparable results as compared to surgical aortic
valve replacement (SAVR).2, 3 Recently the procedure
was approved to include intermediate surgical risk
patients based on PARTNER 2 cohort.4 Although the
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very definition of the high risk population predicts
a high mortality rate, we elected to review our
early experience after performing more than 50
TAVR procedures to see if we could identify clinical
characteristics at baseline or immediately following
the procedure that would predict early death (death
within one year) in our high risk population. To
facilitate such identification, we chose to employ
various machine learning methods effective in
predicting categorical outcomes.5
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METHODS

STATISTICAL ANALYSIS

Charts of all patients assigned to receive TAVR
procedure at St Mary’s Medical Center, Huntington,
West Virginia between April 2013 and November
2016 were identified and reviewed. A total of
72 high-risk cases were included. One of these
patients died prior to undergoing the procedure.
Pre-procedural, procedural, and post-procedural
data were obtained and analyzed. The baseline
characteristics of these patients are shown in Table
1. Primary outcomes were identified as all cause
mortalities and strokes at index hospitalization, 30
days, and 12 months. Secondary outcomes data were
identified as access site complications, heart failure
symptoms, renal failure, length of stay, and postprocedural valvular hemodynamics.

All analysis was performed using the open source
program R. The data was cleaned by excluding
variables with large numbers of missing values.
Variables with more moderate amounts of missing
values that had numeric data had the average value
placed into missing value categories. Analysis of
72 subjects was then possible. Machine learning
was performed on a dataset without missing
values. Parameters used for subsequent analysis
are shown in Table 1. Before deciding to analyze the
dataset without missing values, multiple methods
of imputation for both missing categorical and
continuous data were employed and yielded results
similar to analysis on the cleansed data.
Logistic Regression and Support V ector Machine
We used a generalized linear
(logistic regression) model as
our default6 using only baseline
variables for the prediction of
composite endpoint outcomes.
In addition, we examined the
utility of a support vector machine
(SVM) which involves the multidimensional sorting of data
based on the development of a
hyperplane which best segregates
the two classes.8 Using the CARET
package, we employed two
tuning parameters to control the
performance of the SVM: kernel and
C. We used the radial kernel option
from the CARET package. When
radial kernel is applied, Sigma needs
to be specified to avoid over-fitting.
The second tuning parameter
used was C which specifies the
penalty for misclassification. The
best combination of C and Sigma
values are determined using crossvalidation. Sigma and C values
were optimized within the CARET
package, and values of 1e-4 and 32
were used thereafter.
Random Forest

TABLE 1: Baseline patient characteristics
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The third method we applied is the random forest
which employs decision trees to construct a
predictive model using a set of binary rules applied
to calculate a target value. We used two tuning
parameters for random forest: the number of trees
(ntree) averaged (1000) and the number of variables
(mtry=9) randomly sampled as candidates at each
split in each tree. The mtry parameter was varied and
optimized using the ROC on the training set.7.8

RESULTS
A total of 72 patients underwent TAVR. One patient
died before getting the assigned procedure.
Transfemoral access was 88.9%(N=64), Transapical
access was 11.1%(N=8). The characteristics of the
patients at baseline are shown in Table 1. Valve types
used are shown in Table 2.

Neural Network
We also tried a feed-forward neural network.
Different feed forward neural network architectures
were explored using the nnet and neuralnet
packages.9 We found optimal performance with one
hidden layer containing 9 hidden neurons with a
decay value 0.24 after initial exploration.
Model Comparisons
The CARET package was used for comparison of the
mature models employing 10 folds and 3 repeats.10
Other packages within R were used for different
specific tasks (e.g., nnet for construction of the
neural network, random forest (randomForest) for
constructing random forests).9,11-15 All numeric data
were centered and scaled prior to analysis with all
of the above methods. The R code used for these
analyses is shown in appendix 1.
Training and Test Sets
In the first phase, we varied tuning parameters on
a training subset with the CARET package. For the
support vector machine, the sigma and c values
were varied from 0.1 to 1. Once these parameters
were optimized for the different methods, we used
different seed values to split the training and testing
sets (50% training:50% testing). We then employed
the strategy of 3 repeats of the 10 folds with CARET
on the different training subsets achieved varying
the seed to initiate randomization to divide the set
into training and testing subsets.
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TABLE 2: Valve types

Death and Stroke
Death rate from any cause at 12 months was
19.4%(N=14) of which 4(5.6%) died during index
hospitalization and one (1.3%) at 30 days. Stroke
incidence at 12 months was 8.3%(N=6) of which
two patients (2.8%) had stroke during index
hospitalization, no new cerebrovascular events at 30
days.
Major multivariate predictors of death from any
cause at 12 months are presented in Table 3 and
Figure 1. Comparison of those with and without
early death (< 12 months) is shown in Table 4.
P rocedure outcomes
The procedure was aborted in one patient due to
inability to pass the valve through transfemoral
approach. Patient died before getting transapical
approach. None of the patients required conversion
to open surgical approach. A total of 5 (6.9%)
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TABLE 3: Mean and Standard Error of Mean (SEM) of Receiver Operator Curve (ROC) values utilizing
different techniques. Top five predictor variables of death at 12 months.

FIGURE 1: Receiver operator curves (ROC) in one of the techniques showing
sensitivity against specificity for generalized linear model (GLM)
– red color, area under curve (AUC) = 0.56, support vector machine (SVM)
– green color, AUC=0.63, neural network (NNet)
– orange color, AUC= 0.63, random forest (RFor)
– purple color, AUC= 0.63
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TABLE 4: Comparison of those with and without early death (< 12 months)
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patients required PCI at or within 30 days prior to the
procedure. All transfemoral (88.9%, N=64) approach
patients performed utilizing arterial cut down for
sheath access. Combined access site complications
rate was 5.6%(N=4). Major and minor access site
hematoma rate was 4.2%(N=3). 33.3%(N=24) patients
required at least 1 unit of red blood cell transfusion.
Mean contrast volume was 108 milliliters.
Other clinical outcomes
There was a significant reduction in symptoms to
New York Heart Association (NYHA) class I or II at
follow up visits. There was a significant increase
in Kansas City Cardiomyopathy Questionnaire
(KCCQ) points at 30 days (P< 0. 02) and 12 months
(P=<0.02) follow up. Mean KCCQ before TAVR was 29,
which increased to 54 and 53 at 30 days and 1 year
respectively. Mean post procedure GFR (55.9±23.2).
Rate of new onset left bundle branch block (LBBB)
was 27.7%(N=20). Five patients (6.9%) required
new permanent pacemaker (PPM) placement. A
total of 4(5.5%) patients developed new onset atrial
fibrillation.
Echocardiographic data
Aortic Valve Area (AVA) showed a significant increase
as compared to baseline (P= 0.000000001662, t=6.9), with a mean post procedure AVA of (2.4 CM2
±2.0). There was a significant reduction in the mean
gradient across aortic valve (P=< 0.022), average
post procedure mean gradient (10.6 mmHg ± 5.3).
Mean post procedure aortic regurgitation including
paravalvular and valvular jets was mild. Ejection
fraction showed improvement post intervention
with mean value of 52% as compared to 48% preintervention relation to outcome are shown in Table
4.
DISCUSSION
We evaluated the high-risk population who
underwent TAVR at our institution at the very
beginning of our TAVR program. Variable baseline
risk factors and elevated pre-procedure Society of
Thoracic Surgery (STS) risk score predict increased
mortality.16 Interestingly, in our study the three
major predictors of mortality within twelve months
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were procedural related factors, however no
statistical significance was noted possibly due to
small sample size. Not surprisingly, two out of three
elements were renal related. Acute Kidney Injury
(AKI) is a frequently encountered complication
post TAVR.17, 18 Several predictors of AKI have been
studied.19 Pre existing chronic kidney disease,
respiratory failure, blood transfusion, previous
stroke, frequent intraprocedural valve reposition,
periprocedural embolization, hemodynamic
instability associated with rapid pacing, and use of
contrast medium were strong predictors for acute
kidney injury.18, 20
In our study contrast media volume was a predictor
for increased 12 months mortality. Nevertheless,
limiting contrast use is a priority during TAVR;
complexity of cases, however, may mandate the
opposite. Interestingly, a meta-analysis of four
cohort studies which included 891 TAVR patients did
not show a significant association between contrast
media volume and risk of AKI, 21 however the small
number of the included studies is a limitation of the
analysis. Thus further studies may be warranted
to evaluate whether contrast media volume alone
without AKI is a potential independent surrogate
for increase mortality post TAVR. New onset AKI
demonstrated worse short and long prognostic
impacts among TAVR population. According to a
meta-analysis of 5,971 patients, post procedure
AKI was associated with increased all cause and
cardiovascular mortality early and at 12 months.22
RenalGuard system utilizing furosemide induced
diuresis with matched isotonic saline may be an
effective tool in reducing incidence of post TAVR
AKI.23, 24
Valve designs and procedural techniques have
evolved significantly over the recent period. Lower
valve profile has enhanced valve deliverability and
reduced complications. Sheath size has decreased
significantly from 24 French (Fr) to 14-16 Fr thus
reducing the need for arterial cut down and access
site complications. Moreover, addition of an external
skirt to the balloon expandable valves (Sapien XT,
Sapien 3) reduced paravalvular regurgitation.25
In our sample only four patients demonstrated
access site complications, however majority of the
valves were early generation with higher profile
and required arterial cut down in nearly all of the
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transfemoral cases. Despite using early generation
valves in the majority of cases, the mean degree of
paravalvular regurgitation was mild.
Thirty days and 12 months stokes rates were
2.8%(N=2), and 8.3%(N=6) respectively. Our 30
days rate is lower than results reported in large
prospective cohorts (2.8% vs. 5% in the PARTNER
trial), while our 12 months results are comparable
(8.3 vs. 7.8).3, 4 Neurological events post TAVR are
classified as early within first 24-48 hours (procedural
related), delayed between 2-30 days, and late after
30 days (patient and disease related factors).26 Small
aortic valve area, balloon post dilatation, and atrial
fibrillation are associated with increased incidence
of early cerebrovascular accidents (CVAs). Chronic
atrial fibrillation, prior cerebrovascular disease, and
transapical approach are some predictors of late
CVAs.27 Currently there is controversy about the
benefit of embolic protection devices, however
recent meta-analysis of randomized control trials
demonstrated promising role in stroke reduction;
future large studies may answer this question.28
Sedation technique during the procedure has
evolved since the advent of TAVR. Initially the
procedure was only done under general anesthesia,
as is the case in our early sample. However, currently
most of the TAVR in our institution are performed
under conscious sedation. Hence ICU hours and
cost of care have significantly reduced by using
conscious sedation.29 Finally, we have noticed that
mono-antiplatelet therapy (MAPT) in our population
was a strong predictor of increased 12 months
mortality. The current consensus is utilizing heparin
during the procedure and dual antiplatelet therapy
(DAPT) for 6 months following the implantation
of the valve.30 Interestingly, a large meta-analysis
showed conflicting results regarding dual versus
single antiplatelet therapy.31, 32 Analysis of nine
studies, which included 7991 patients, demonstrated
a significant reduction in mortality and a slight
benefit in stroke prevention without increase in
major bleeding, as compared to MAPT alone.31
Addition of oral anticoagulation to MAPT did not
show any benefit when it compared to DAPT in the
same meta-analysis. However, another meta-analysis
of six studies which included 840 patients showed
increased bleeding risk with DAPT, with no reduction
in mortality, stroke, or myocardial infarction.32 Hence,
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despite its increasing use, the optimal antiplatelet
management of patients undergoing TAVR remains
uncertain. Given our small sample size, further
multicenter studies are warranted to delineate the
association between MAPT and mortality risk among
TAVR population.
In conclusion, we found that post procedure GFR,
less number of antiplatelet agents post procedure,
and contrast volume may predict mortality within
first 12 months post TAVR. Further studies focused
on the above factors may be warranted.
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